In vivo drug release behavior and osseointegration of a doxorubicin-loaded tissue-engineered scaffold
| Autor: | Haisheng Li, Frederik Dagnæs-Hansen, Muwan Chen, Mogens Johannsen, Miao Wang, Cody Bünger, Jakob Hansen, Jørgen Kjems, Ming Sun, Anette Baatrup, Dang Quang Svend Le, Jan Duedal Rölfing, Helle Lysdahl, Jonas Jensen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Drug Scaffold General Chemical Engineering media_common.quotation_subject 02 engineering and technology General Chemistry Bone healing Pharmacology 021001 nanoscience & nanotechnology Osseointegration Chitosan 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology chemistry In vivo medicine Alkaline phosphatase Doxorubicin 0210 nano-technology media_common medicine.drug |
| Zdroj: | Sun, M, Chen, M, Wang, M, Hansen, J, Baatrup, A, Dagnæs-Hansen, F, Rölfing, J D, Jensen, J, Lysdahl, H, Li, H, Johannsen, M, Le, D Q S, Kjems, J & Bünger, C 2016, ' In vivo drug release behavior and osseointegration of a doxorubicin-loaded tissue-engineered scaffold ', RSC Advances, vol. 6, pp. 76237-76245 . https://doi.org/10.1039/c6ra05351c |
| Popis: | Bone tissue-engineered scaffolds with therapeutic effects must meet the basic requirements as to support bone healing at the defect side and to release an effect drug within the therapeutic window. Here, a rapid prototyped PCL scaffold embedded with a chitosan/nanoclay/β-tricalcium phosphate composite (DESCLAYMR) loaded with the chemotherapeutic drug doxorubicin (DESCLAYMR_DOX) is proposed as a potential multifunctional medical application for patients who undergo bone tumor resection. We showed the DESCLAYMR_DOX scaffold released DOX locally in a sustained manner in mice without significantly increasing the plasma DOX concentrations. The evaluation of osseointegration in a porcine study showed increased mineralized bone formation, unmineralized collagen fibers and significantly higher alpha Smooth Muscle Actin (α-SMA) positive areas relative to the total investigated area (TA) in defects treated solely with the DESCLAYMR scaffold than in the DESCLAYMR_DOX; and alkaline phosphatase activity, α-SMA/TA and bone formation were higher in the DESCLAYMR loaded with 100 μg per scaffold DOX (DOX_low) than with 400 μg per scaffold DOX (DOX_high). Our results suggest that the DESCLAYMR_DOX can be a viable candidate as a multifunctional medical application by delivering the chemotherapeutic agent to target remaining tumor cells and facilitate bone formation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|